A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Ovid takes another big swing in neuroscience under a new CEO
Ovid takes another big swing in neuroscience under a new CEO
Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift
Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift
A protein model designed for space could expand pharma’s definition of ‘druggability’
A protein model designed for space could expand pharma’s definition of ‘druggability’
New FDA guidance that’s a ‘huge deal’ for clinical trials
New FDA guidance that’s a ‘huge deal’ for clinical trials
In a tough market, biotechs can be their own worst enemy
In a tough market, biotechs can be their own worst enemy
New diagnostics define drug targets for Alzheimer’s, Parkinson’s and beyond
New diagnostics define drug targets for Alzheimer’s, Parkinson’s and beyond
Bayer sets the stage for a pharma comeback
Bayer sets the stage for a pharma comeback
The most valuable up-and-coming GLP-1s
The most valuable up-and-coming GLP-1s
Big Pharma CEOs set sights on massive growth in years to come
Big Pharma CEOs set sights on massive growth in years to come
Why TrumpRx is stumbling before it gets off the ground
Why TrumpRx is stumbling before it gets off the ground
Investors crave safer, market-ready biotech bets, widening the early-stage funding gap
Investors crave safer, market-ready biotech bets, widening the early-stage funding gap
Mirum doubles down on diversified rare disease strategy
Mirum doubles down on diversified rare disease strategy
AI regulation lags despite entering higher-risk patient care
AI regulation lags despite entering higher-risk patient care
Pharma’s outlook in 2026: Smoother sailing ahead?
Pharma’s outlook in 2026: Smoother sailing ahead?
How Big Pharma is navigating a $300 billion patent cliff
How Big Pharma is navigating a $300 billion patent cliff
Politicization runs deeper than ever at FDA, risking long-term impacts
Politicization runs deeper than ever at FDA, risking long-term impacts
Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential
Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential
Has Novavax cracked the code for survival in the vaccine arena?
Has Novavax cracked the code for survival in the vaccine arena?
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page